CytomX Therapeutics Inc (CTMX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.76 (-2.13%), Market cap $0.84B, 52-week low–high $1.76 ~ $6.75.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor recep
Financial statements, price targets, institutional (13F) holdings and related news for CytomX Therapeutics Inc are updated in real time on BlackAll Trade.
CytomX Therapeutics Inc trades at $2.76 (-2.13%). Real-time quotes and charts are available on BlackAll Trade.
CytomX Therapeutics Inc has a market cap of about $0.84B.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes condition